Skip to main content

Advertisement

SpringerLink
Log in

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers

  • Brief Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

It is unclear if earlier onset (<40 years) and greater proliferative capacity confer an equally poor prognosis to endocrine-dependent and endocrine-independent breast cancers. Available outcome (distant metastasis-free survival, DMFS) and expression microarray data from 621 adjuvant treatment-naïve, node-negative primary breast cancers were pooled for prognostic evaluation of age-at-diagnosis (<40 years vs. ≥40 years) and tumor proliferative capacity relative to estrogen receptor status (n = 400 ER-positive, n = 221 ER-negative). Transcriptome measures of proliferative capacity included a proliferation score (PS) based on a 61-gene proliferation signature and the single gene surrogate, FOXM1. Kaplan–Meier analyses revealed no significant difference in DMFS between ER-positive and ER-negative cases >5 years after diagnosis. In contrast, younger age and higher proliferative capacity resulted in significantly more metastatic events cumulated over 15 years, but only in ER-positive breast cancers where positive correlations between age and proliferation were observed. While strongly correlated, FOXM1 and PS did not appear equivalent in relation to age and prognosis. The poor prognosis associated with breast cancer arising before age 40 or with higher proliferative capacity pertains only to endocrine-dependent (ER-positive) breast cancer, indicating that different biological processes drive the metastatic potential of ER-negative breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Benz CC (2008) Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 66(1):65–74

    Article  PubMed  Google Scholar 

  2. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330. doi:10.1200/jco.2007.14.2471

    Article  PubMed  Google Scholar 

  3. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4(11):e7695

    Article  PubMed  Google Scholar 

  4. Peppercorn J (2009) Breast cancer in women under 40. Oncology 23(6):465–474

    PubMed  Google Scholar 

  5. Peppercorn J, Partridge AH (2008) Breast cancer in young women: a new color or a different shade of pink? J Clin Oncol 26(20):3303–3305. doi:10.1200/jco.2008.16.5621

    Article  PubMed  Google Scholar 

  6. Jatoi I, Anderson WF, Rosenberg PS (2008) Qualitative age-interactions in breast cancer: a tale of two diseases? Am J Clin Oncol 31(5):504–506. doi:510.1097/COC.1090b1013e3181844d3181841c

    Article  PubMed  Google Scholar 

  7. Eppenberger-Castori S, Moore IIDH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC (2002) Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34(11):1318–1330

    Article  PubMed  CAS  Google Scholar 

  8. Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray J, Chew K, Dairkee S, Moore D, Schittulli F, Tommasi S, Paradiso A, Albertson D, Benz C (2007) Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res 9(5):R59

    Article  PubMed  Google Scholar 

  9. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679

    PubMed  CAS  Google Scholar 

  10. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massagua J (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci 104(16):6740–6745. doi:10.1073/pnas.0701138104

    Article  PubMed  CAS  Google Scholar 

  11. Desmedt C, Piette F, Loi S, Wang Y, Lallemand Fo, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’ Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13(11):3207–3214. doi:10.1158/1078-0432.ccr-06-2765

    Article  PubMed  CAS  Google Scholar 

  12. van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967

    Article  PubMed  Google Scholar 

  13. Clark GM (2000) Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 489–514

    Google Scholar 

  14. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F (2008) Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer 8(1):339

    Article  PubMed  Google Scholar 

  15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752

    Article  PubMed  CAS  Google Scholar 

  16. Ly DH, Lockhart DJ, Lerner RA, Schultz PG (2000) Mitotic misregulation and human aging. Science 287(5462):2486–2492. doi:10.1126/science.287.5462.2486

    Article  PubMed  CAS  Google Scholar 

  17. Laoukili J, Stahl M, Medema RH (2007) FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775(1):92–102

    PubMed  CAS  Google Scholar 

  18. Marron JS, Todd MJ, Ahn J (2007) Distance-weighted discrimination. J Am Stat Assoc 102:1267–1271

    Article  CAS  Google Scholar 

  19. Hu Z, Fan C, Oh D, Marron JS, He X, Qaqish B, Livasy C, Carey L, Reynolds E, Dressler L, Nobel A, Parker J, Ewend M, Sawyer L, Wu J, Liu Y, Nanda R, Tretiakova M, Orrico A, Dreher D, Palazzo J, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush J, Ellis M, Olopade O, Bernard P, Perou C (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7(1):96

    Article  PubMed  Google Scholar 

  20. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC (2010) A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12(5):R85

    Article  PubMed  Google Scholar 

  21. Pusztai L (2009) Gene expression profiling of breast cancer. Breast Cancer Res 11(3):S11

    Article  PubMed  Google Scholar 

  22. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. doi:10.1056/NEJMoa041588

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Institutes of Health [U24-CA14358 to C.C.B., R01-AG-020521 to C.C.B., R01-CA071468 to C.C.B, P50-CA58207 to C.C.B., and P01-AG025901 to C.C.B.]; the Netherlands Genomic Initiative/Netherlands Organization for Scientific Research [to J.A.F.]; and Hazel P. Munroe memorial funding [to the Buck Institute]. We appreciate critical input from our University of California at Santa Cruz (UCSC)-Buck Institute TCGA-GDAC collaborators.

Author information

Authors and Affiliations

  1. Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA, 94945, USA

    Christina Yau & Christopher C. Benz

  2. Veridex LLC, Johnson and Johnson, San Diego, CA, 921221, USA

    Yixin Wang

  3. Pfizer Global Pharmaceutical, Research and Development, La Jolla, CA, 92121, USA

    Yi Zhang

  4. Erasmus MC Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, 3015 GE, Rotterdam, The Netherlands

    John A. Foekens

  5. Comprehensive Cancer Center and Division of Oncology-Hematology, University of California, San Francisco, CA, 94143, USA

    Christopher C. Benz

Authors
  1. Christina Yau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yixin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John A. Foekens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher C. Benz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher C. Benz.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yau, C., Wang, Y., Zhang, Y. et al. Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat 126, 803–810 (2011). https://doi.org/10.1007/s10549-011-1345-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1345-1

Keywords

Search

Navigation